Cadence Biomedical Announces $1.2M Series B Funding Close

Seattle, WA – June 24, 2015 – Cadence Biomedical, the manufacturers of Kickstart®, designed to enable walking and accelerate therapeutic outcomes for stroke and other neurological conditions, today announced the close of a $1.2M Series B investment round. The round was led by HealthTech Capital and included participation from BioPacific Investments, Frontier Angel Fund, and individual investors. The new funds will be used to expand sales and marketing activities to drive adoption of Kickstart throughout the country.